Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 30;23(9):5023.
doi: 10.3390/ijms23095023.

Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade

George Crișan  1   2 , Nastasia Sanda Moldovean-Cioroianu  1 , Diana-Gabriela Timaru  1 , Gabriel Andrieș  2 , Călin Căinap  3 , Vasile Chiș  1   4
Affiliations

Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade

George Crișan et al. Int J Mol Sci. .

Abstract

Positron emission tomography (PET) uses radioactive tracers and enables the functional imaging of several metabolic processes, blood flow measurements, regional chemical composition, and/or chemical absorption. Depending on the targeted processes within the living organism, different tracers are used for various medical conditions, such as cancer, particular brain pathologies, cardiac events, and bone lesions, where the most commonly used tracers are radiolabeled with 18F (e.g., [18F]-FDG and NA [18F]). Oxygen-15 isotope is mostly involved in blood flow measurements, whereas a wide array of 11C-based compounds have also been developed for neuronal disorders according to the affected neuroreceptors, prostate cancer, and lung carcinomas. In contrast, the single-photon emission computed tomography (SPECT) technique uses gamma-emitting radioisotopes and can be used to diagnose strokes, seizures, bone illnesses, and infections by gauging the blood flow and radio distribution within tissues and organs. The radioisotopes typically used in SPECT imaging are iodine-123, technetium-99m, xenon-133, thallium-201, and indium-111. This systematic review article aims to clarify and disseminate the available scientific literature focused on PET/SPECT radiotracers and to provide an overview of the conducted research within the past decade, with an additional focus on the novel radiopharmaceuticals developed for medical imaging.

Keywords: PET; SPECT; molecular imaging; radiopharmaceuticals; review; tracers.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Number of scientific papers related to PET (left axis) and SPECT (right axis) radiopharmaceuticals over the past 10 years.
See this image and copyright information in PMC

References

    1. Cuocolo A., Petretta M. PET and SPECT Specialty Grand Challenge. When Knowledge Travels at the Speed of Light, Photons Take to the Field. Front. Nucl. Med. 2021;1:671914. doi: 10.3389/fnume.2021.671914. - DOI
    1. Van der Meulen N.P., Strobel K., Lima T.V.M. New Radionuclides and Technological Advances in SPECT and PET Scanners. Cancers. 2021;13:6183. doi: 10.3390/cancers13246183. - DOI - PMC - PubMed
    1. Wadsak W., Mitterhauser M. Basics and principles of radiopharmaceuticals for PET/CT. Eur. J. Radiol. 2010;73:461–469. doi: 10.1016/j.ejrad.2009.12.022. - DOI - PubMed
    1. Lau J., Rousseau E., Kwon D., Lin K.S., Bénard F., Chen X. Insight into the Development of PET Radiopharmaceuticals for Oncology. Cancers. 2020;12:1312. doi: 10.3390/cancers12051312. - DOI - PMC - PubMed
    1. Lee Y.S. Radiopharmaceuticals for Molecular Imaging. Open Nucl. Med. J. 2010;2:178–185. doi: 10.2174/1876388X01002010178. - DOI

Publication types

Substances